1. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
- Author
-
Palanques-Pastor, Tomás, Megías-Vericat, Juan Eduardo, Martínez, Pilar, López Lorenzo, José Luis, Cornago Navascués, Javier, Rodriguez Macias, Gabriela, Cano, Isabel, Arnan Sangerman, Montserrat, Vidriales Vicente, María Belén, Algarra Algarra, Jesús Lorenzo, Foncillas, María Ángeles, Herrera, Pilar, Botella Prieto, Carmen, Vives, Susana, Figuera Álvarez, Ángela, Cuevas Palomares, Laida, Sobas, Marta, Contento Gonzalo, Alejandro, Cuello García, Rebeca, and Amutio Diez, María Elena
- Subjects
ACUTE myeloid leukemia ,SARS-CoV-2 ,TREATMENT effectiveness ,ADULTS ,PATIENTS' attitudes - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March–May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF